Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

PartnershipKeytrudaPositive

AI Analysis

Summary

Cipla's Invagen Pharmaceuticals entered into an exclusive partnership with Qilu Pharmaceutical for licensing and supply of a Keytruda (Pembrolizumab) biosimilar in the US market.

Importance:7/10

Sentiment:

0.40

biosimilarlicensingpartnershipPembrolizumabUS market

Related Companies

$CIPLA

Read the original article

Published by PR Newswire Pharma on September 3, 2026 4:23 PM

Read Original